PO-0856 Metastasis-directed therapy for oligoprogressive castration refractory prostate cancer. (April 2019) - Berghen, C.; Joniau, S.; Ost, P.; Poels, K.; Everaerts, W.; Haustermans, K.; De Meerleer, G.